

FORMULATION AND EVALUATION OF ETHANOLIC EXTRACT OF *CRYPTOLEPIS SANGUIOLENTA* ROOT TABLETS

¹CHIME SALOME A, ¹ONYISHI V.I, ²MOMOH M. A., ¹ONUNKWO GODSWILL C.

¹Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka 410001, Nigeria, ²Department of Pharmaceutics, University of Nigeria, Nsukka 410001, Nigeria. Email: emmyrachi@yahoo.com; salome.chime@unn.edu.ng

Received: 27 July 2013, Revised and Accepted: 8 August 2013

ABSTRACT

Objectives: To study were to formulate the ethanolic extract of *Cryptolepis sanguinolenta* root into tablets and to evaluate the effect of different binders and binder concentration on the properties of tablets.

Materials and method: The phytochemistry of ethanolic extract of *Cryptolepis sanguinolenta* was evaluated. The tablets were formulated by wet granulation using gelatin and sodium carboxymethyl cellulose (SCMC) as binders at concentrations of 2 %, 4 %, 6 % and 8 % w/w. The tablets were evaluated using the necessary official and unofficial tests.

Results: Phytochemical analysis revealed the presence of alkaloids, terpenoids, steroids, proteins, carbohydrate, resins, reducing sugars and glycosides. Tannins, saponins, flavonoids and acidic compounds were absent. The tablets passed the uniformity of weight test and deviations obtained complied with BP specifications. Tablets disintegration time ranged from 8.00 ± 0.10 to 13.50 ± 0.21 min for tablets formulated with 2 and 4 % gelatin and 10.00 ± 0.17 to 31.00 ± 0.27 min for tablets formulated with 2 and 8 % SCMC. *C. sanguinolenta* tablets formulated gelatin significantly showed higher hardness values than SCMC ($p < 0.05$). Tablets showed friability of approximately ≤ 1 %.

Conclusion: Therefore, gelatin showed good properties for formulating *Cryptolepis sanguinolenta* normal release tablets than SCMC.

Keywords: *Cryptolepis sanguinolenta*, phytochemistry, wet granulation, antimalaria

INTRODUCTION

Cryptolepis sanguinolenta is a thin-stemmed twining and scrambling shrub up to 8 m long, containing yellow-orange juice which becomes red upon drying. It is a member of the family Apocynaceae (subfamily: Periplocoideae). The plant is native to West Africa and is found in countries like Ghana, Nigeria, Cote d'Ivoire, Guinea, Guinea-Bissau, Mali, Senegal, Sierra Leone, Angola, Congo, Uganda, and Cameroon [1]. It is a medicinal plant used by some traditional herbalist in the treatment of fever, urinary, and upper respiratory tract infections [1]. The use of this plant as a medical therapy has increased as it has been proposed that the root and leaf extracts have hypotensive, antipyretic, anti-inflammatory, antidiarrhoeal, *in vitro* antibacterial and antimalarial effects [2]. It is commonly called *nibima*, *Kadze*, *gangamauo*, or yellow-die root. It is called *paran pupa* in the Yoruba-speaking areas of Nigeria [1]. Studies have documented the antidiabetic potentials of *Cryptolepis sanguinolenta* [3-5]. Crude extracts of *C. sanguinolenta* and their fractions, as well as indoquinoline alkaloids isolated from the plant, have been shown to have activity against *Plasmodium falciparum* both *in vitro* and *in vivo* [6-8]. In addition to studies indicating anti-plasmodial effect, extracts of *C. sanguinolenta* have been shown to have anti-microbial [9-10], and anti-inflammatory activities [6]. Extracts from various morphological parts of *Cryptolepis sanguinolenta* are widely used traditionally in folklore medicine in many parts of the world for the management, control, and treatment of diabetes mellitus. The hypoglycemic activity of *Cryptolepis sanguinolenta* is associated with its influence to reduce intestinal glucose absorption and transport [6].

The primary benefit of using plant-derived medicine is that they are relatively safer than synthetic alternatives, offering profound therapeutic benefits and more affordable treatments [11]. In recent times, focus on plant research has increased all over the world and a lot of evidence has been collected to show immense potential of medicinal plants used in various traditional systems [12]. Plants may become the bases for the development of a new medicine or they may be used as phyto-medicine for the treatment of disease [13]. It is estimated that today, plant materials are present in, or have

provided the models for 50 % Western drugs [14]. Plant derived drug serve as a prototype to develop more effective and less toxic medicine [15]. Plants with anti malarial, antihelmintic, antidiabetic and anti-inflammatory properties have been of immense ethnomedicinal use to mankind. In view of the widespread use of herbal products, important technical aspects such as standardization and quality control will be of immense benefit in order to enhance their efficacy and improve patient's compliance [16].

Tablet dosage forms are the most popular and preferred drug delivery systems in terms of precision of unit dose, low cost, patient compliance, and good physical and chemical stability and account for 70 % - 80 % of all pharmaceutical dosage forms [17]. Tablets have remained the most common dosage form by which medicaments are usually administered to patients because of their advantages over the other dosage forms [18]. Therefore the objective of this work is to formulate the methanolic extract of *Cryptolepis sanguinolenta* into tablets and to study the effect of different binders and binder concentration on the *in vitro* properties of the tablets.

MATERIALS AND METHODS

Lactose (Merck, Germany), maize starch, sodium carboxymethyl cellulose, gelatin, ethanol (BDH, England), magnesium stearate (May and Baker, England), distilled water (Lion water, Nsukka, Nigeria). *Cryptolepis sanguinolenta* root extract was obtained from a batch processed in our laboratory. All other reagents and solvents were analytical grade and were used as supplied.

Collection and authentication of plant material

Cryptolepis sanguinolenta roots were collected from the Army Barrack's field along Edem road Nsukka, Enugu State, Nigeria in the month of June, 2011. The plant material was authenticated by Mr. A.O. Ozioko, a consultant taxonomist with the International Center for Ethnomedicine and Drug Discovery (InterCEDD) Nsukka. The voucher specimen of the plant was deposited in the herbarium of the Department of Pharmacognosy and Environmental Medicines, University of Nigeria, Nsukka.

Preparation of plant extract for phytochemical analysis

Cryptolepis sanguinolenta roots were washed thoroughly in water, chopped into tiny pieces then dried in an air-circulating oven in the laboratory at 35 – 40°C. The dried roots were milled severally in an equipment of hammer mill type. The powdered roots (210 g) were extracted by maceration with 95 % ethanol for 48 h. The extract was filtered and concentrated to dryness using a rotary evaporator attached to a vacuum pump to obtain the crude powdered extract (10 g) which was stored at a temperature of 40°C until use.

Phytochemical Screening

Phytochemical tests were carried out on the powdered extract for the presence of alkaloids, tannins, saponins, flavonoids, resins, fats and oils, steroids, glycosides, terpenoids, acidic compounds,

carbohydrates, reducing sugars and proteins. The tests were carried out using standard procedures of analysis [18-20].

Preparation of granules

Granules were prepared by wet granulation method using two different binders at concentrations of 2 %, 4 %, 6 % and 8 %w/w. Details of granulation are given in Table 1. Lactose was used as the filler and maize starch BP as disintegrant (10 % w/w) were dried and mixed for 10 min in a tumbler mixer with the crude extract of *Cryptolepis sanguinolenta*. The powder mixtures were moistened with the appropriate amount of binder solution. The homogeneous wet mass was then screened through a 1.7 mm sieve and the wet granules dried in a hot air oven at 55°C for 1 h. Thereafter, the dried granules were screened through a 1.0 mm sieve.

Table 1: Composition of *Cryptolepis sanguinolenta* tablet

Batch	<i>C. sanguinolenta</i> extract (mg)	Gelatin (mg)	SCMC (mg)	Maize starch (mg)	Magnesium stearate (mg)	Lactose qs (mg)
F1	5.0	6.0	-	15.0	3.0	300.0
F2	5.0	12.0	-	15.0	3.0	300.0
G1	5.0	-	6.0	15.0	3.0	300.0
G2	5.0	-	12.0	15.0	3.0	300.0
G3	5.0	-	18.0	15.0	3.0	300.0
G4	5.0	-	24.0	15.0	3.0	300.0

Key: F1 and F2 contain 2 and 4 %w/w gelatin, G1 – G4 contain 2, 4, 6, and 8 %w/w SCMC, SCMC: sodium carboxymethyl cellulose.

Preparation of tablets

Initially granules were treated with lubricant i.e. magnesium stearate. Tablets were prepared by compressing the lubricated granules at 46-48 kgf using a 9.0 mm punch and die set fitted into an automated F3 Manesty Single Punch tableting machine.

EVALUATION OF TABLETS

Disintegration time test

Disintegration time test was conducted using an Erweka ZT 120 basket and rack assembly and 0.1 N HCl maintained at 37.0 ± 1.0 °C as the disintegration medium. Ten tablets from each batch were used for the test and the procedure being as stipulated in the BP, 2009 for normal release tablets [21].

Uniformity of Weight

Twenty tablets were randomly selected from each batch. The tablets were weighed individually using an electronic balance (Ohaus Adventurer, China) and the individual weights recorded. The mean weight, standard deviation and percentage deviation were calculated [21].

Tablet friability test

Twenty tablets were randomly selected from each batch of the tablet. The tablets were dedusted and weighed. The tablets were placed into the drum of the friabilator (Erweka GmbH, Germany) and rotated at 25 rpm for 4 min. The tablets were removed from the friabilator, dedusted and reweighed. The friability result was expressed as loss of mass expressed as a percentage of the initial mass [21]. The abrasion resistance B was calculated from the equation below:

$$B = 100 \left[1 - \frac{W}{W_0} \right] \quad (1)$$

where W_0 and W are the initial weight and final weight of the tablets respectively.

Hardness/Crushing Strength Test

This test was carried out using a Monsanto-stokes hardness tester. Ten tablets from each batch were randomly selected. Each tablet was placed between the jaws of the hardness tester and force was applied by adjusting the knob of tester until the tablet integrity failed. The results were recorded in kgf.

Statistical analysis

Statistical analysis was carried out using SPSS version 14.0 (SPSS Inc. Chicago, IL, USA). All values are expressed as mean ± SD. Data were analysed by one-way analysis of variance (ANOVA). Differences between means were assessed by a two-tailed student's T-test. $P < 0.05$ was considered statistically significant.

RESULTS

Phytochemical constituents of *C. sanguinolenta* root extract

Results of phytochemical screening of *Cryptolepis sanguinolenta* root extract are shown in Table 2. The results indicated the presence of very important phytochemicals. Phytochemical analysis of *Cryptolepis sanguinolenta* root revealed the presence of alkaloids, terpenoids, steroids, proteins, carbohydrate, resins, reducing sugars and glycosides in substantial quantities. Tannins, saponins, flavonoids and acidic compounds were however, not found in the plant root.

TABLET PROPERTIES

Weight uniformity

The results of tablets weight uniformity test presented in Table 3 showed that weights of *C. sanguinolenta* tablets ranged from 310.95 ± 2.42 to 311.15 ± 1.76 mg for batches F1 and F2 formulated with 2 and 4 % gelatin, 294.55 ± 1.65 to 303.90 ± 2.60 mg for tablets G1 and G2 formulated with 2 and 4 % SCMC. The low coefficient of variation exhibited by these formulations confirmed the reproducibility of these formulations and the reliability of the production process.

Disintegration time

The results of the disintegration time of *C. sanguinolenta* tablets are shown in Table 3. From the results, the tablets exhibited disintegration time range of 8.00 ± 0.10 to 13.50 ± 0.21 min for F1 and F2 tablets formulated with 2 and 4 % gelatin and 10.00 ± 0.17 to 31.00 ± 0.27 min for tablets formulated with 2 and 8 % SCMC (G1 and G4).

Tablets hardness

The results of tablets hardness are shown in Table 3. From the results, *C. sanguinolenta* tablets exhibited hardness that ranged from 4.76 ± 0.05 to 5.80 ± 0.07 kgf for F1 and F2 tablets formulated with 2 and 4 % gelatin and 2.00 ± 0.03 to 5.00 ± 0.07 kgf for tablets formulated with 2 and 8 % SCMC (G1 and G4). Generally, tablets formulated with gelatin showed higher hardness values than SCMC.

Tablets friability

The results of tablets friability test shown in Table 3 showed that tablets friability ranged from 0.84 to 1.28 % for F1 and F2 tablets formulated with 2 and 4 % gelatin and 0.92 to 1.31 % for tablets formulated with 8 and 4 % SCMC (G4 and G2). Friability test measures the resistance of the tablets to abrasion.

DISCUSSIONS

Phytochemical constituents of *C. sanguinolenta* root extract

The presence of alkaloids in high concentration in the plant root explains the traditional use of the plant for the treatment of malaria. The medicinal plants that are moderately rich in alkaloids have potential health promoting effects [22]. Crude extracts of *C.*

sanguinolenta and their fractions, as well as indoquinoline alkaloids isolated from the plant, have been shown to have activity against *Plasmodium falciparum* both *in vitro* and *in vivo* as earlier reported [6-8]. The root of the plant also contains glycosides. Cardiac glycosides treat heart problems that may result from severe malaria attack. Phytochemicals are non-nutritive plant chemicals that have protective or disease preventive properties. Plants produce these chemicals substances to protect themselves, and they also protect humans against certain diseases [23].

Table 2: Phytochemical constituents of *C. sanguinolenta* roots extract

Phytochemical constituents	Remarks
Alkaloids	+++
Carbohydrates	++
Saponins	-
Reducing sugars	+++
Steroids	+++
Tannins	-
Glycosides	+++
Proteins	+++
Flavonoids	-
Resins	+++
Fats and oils	-
Acid compounds	-
Terpenoids	+++

Key: +++ High concentration, ++ moderate concentration, - absent

Table 3: Properties of *C. sanguinolenta* root extract tablets.

Batch	Weight (mg \pm CV)*	Hardness (kgf \pm SD) ^a	Disintegration time (min \pm SD) ^a	Friability (%) [*]
F1 (2 % gelatin)	311.15 \pm 1.76	4.76 \pm 0.05	8.00 \pm 0.10	1.28
F2 (4 % gelatin)	310.95 \pm 2.42	5.80 \pm 0.07	13.50 \pm 0.21	0.84
G1 (2 % SCMC)	303.90 \pm 2.60	2.00 \pm 0.03	10.00 \pm 0.17	1.07
G2 (4 % SCMC)	294.55 \pm 1.65	3.06 \pm 0.03	18.60 \pm 0.11	1.31
G3 (6 % SCMC)	296.30 \pm 1.31	4.18 \pm 0.10	20.10 \pm 0.23	1.04
G4 (8 % SCMC)	296.00 \pm 1.78	5.00 \pm 0.07	31.00 \pm 0.27	0.92

*Mean for 20 tablets, ^aMean for 10 tablets \pm SD, CV: coefficient of variation, SD: standard deviation, F1 and F2 contain 2 and 4 %w/w gelatin, G1 - G4 contain 2, 4, 6, and 8 %w/w SCMC; SCMC: sodium carboxymethyl cellulose, P < 0.05 was considered significant.

Tablet properties

The results of the properties of *C. sanguinolenta* root extract tablets are presented in Table 3. From the results, all the batches of *C. sanguinolenta* tablets formulated with different binders and varying binder concentration passed the uniformity of weight test and deviations obtained complied with BP standards of not more than 5 % for tablets weighing 250 mg or more [21].

The results of disintegration time test of tablets presented in Table 3 showed that tablets formulated with 2 and 4 % of gelatin (F1 and F2) and 2 % SCMC (G1) complied with BP specifications for normal release tablets with disintegration time of < 15 min. However, tablets formulated with 4, 6, and 8 % SCMC (G2, G3 and G4) respectively failed the tablets disintegration time tests with disintegration times that were significantly above 15 min ($p < 0.05$). Therefore, the disintegration time of the tablet formulations was significantly affected by the type of binder and concentration used during formulation ($p < 0.05$). Disintegration time of tablets increased as the concentration of the binder increased as shown in Table 3.

The hardness of the tablet formulations was significantly affected by the type of binder and concentration ($p < 0.05$). *C. sanguinolenta* tablets formulated gelatin significantly showed higher hardness values than SCMC ($p < 0.05$). Tablets hardness also increased as the concentration of the binder increased as shown in Table 3. Tablets formulated with 2 and 4 % gelatin (F1 and F2) complied with BP specifications for tablets hardness with values of ≥ 5 kgf. However, tablets formulated with 2, 4, and 6 % SCMC (G1, G2 and G3) failed

the test for tablets hardness with values < 5 kgf, while tablets formulated with 8 % (G4) passed the hardness test as shown in Table 3. However, tablet hardness may be a function of formulation excipient, physical properties of the granules and compression pressure [24].

Tablets friability results presented in Table 3 showed that *C. sanguinolenta* tablets formulated gelatin and SCMC complied with BP specifications for tablets prepared by wet granulation method with percent friability of approximately ≤ 1 %. Therefore, the tablets could withstand handling, packaging and transportation without compromising the properties of the tablets.

CONCLUSION

Cryptolepis sanguinolenta root extract tablets were produced by wet granulation method using gelatin and SCMC respectively as binders. The properties of the tablets were affected by the binder type and concentration of the binder used in formulating the tablets. Increase in binder concentration caused an increase in hardness and disintegration time of tablets. The results obtained from the study showed that gelatin showed good properties for formulating *Cryptolepis sanguinolenta* normal release tablets than SCMC.

CONFLICT OF INTEREST

The authors state no conflict of interest.

REFERENCES

1. Ajayi AF, Akhigbe RE, Adewumi OM, Okeleji LO, Mujaidu KB, Olaleye SB. Effect of ethanolic extract of *Cryptolepis*

- sanguinolenta stem on in vivo and in vitro glucose absorption and transport: Mechanism of its antidiabetic activity. *Ind J Bierer DE, Dubenko LG, Zhang P, Lu Q, Imbach PA, Garofalo AW, Phuan PW, Fort DM, Litvak J, Gerber RE et al. Antihyperglycemic activities of cryptolepine analogues: An ethnobotanical lead structure isolated from *Cryptolepis sanguinolenta*. J Med Chem 1998; 41:2754-64.*
2. Bierer DE, Fort DM, Mendez CD, Luo J, Imbach PA, Dubenko LG, Dubenko LG, Jolad SD, Gerber RE, Litvak J, Lu Q et al. Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: Its isolation from *Cryptolepis sanguinolenta*, synthesis, and in vitro and in vivo activities. *J Med Chem 1998; 41:894-901.*
 3. Luo J, Fort DM, Carlson TJ, Noamesi BK, Amon-Kotei D, King SR, Tsai J, Quan J, Hobensack C, Lapresca P et al. *Cryptolepis sanguinolenta*: An ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycaemic agent. *Diabet Med 1998; 15:367-74.*
 4. Bugyei KA, Boye GL and Addy ME. Clinical efficacy of a tea-bag formulation of *Cryptolepis sanguinolenta* root in the treatment of acute uncomplicated falciparum malaria. *Ghana Medical Journal 2010, 44 (1):3-10.*
 5. Cimanga K, De Bruyne T, Pieters L, Vlietinck AJ, Turger C.A. In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from *Cryptolepis sanguinolenta*. *J Nat Prod 1997; 60:688-691.*
 6. Grellier P, Ramiaramanana L, Milleriox V, Deharo E, Shrevel J, Frappier F. Antimalarial activity of cryptolepine and isocryptolepine, alkaloids isolated from *Cryptolepis sanguinolenta*. *Phytother Res 1996;10:317- 321.*
 7. Boakye-Yiadom K. Antimicrobial properties of some West African medicinal plants II. Antimicrobial activity of aqueous extracts of *Cryptolepis sanguinolenta* (Lindl.) Schlechter. *Quart J Crude Drug Res 1979; 17:78-80.*
 8. Paulo A, Duarte A, Gomes ET. In vitro antibacterial screening of *Cryptolepis sanguinolenta* alkaloids. *J Ethnopharmacol 1994; 44:127-130.*
 9. Ajali U, Okoye FBC. Antimicrobial and anti-inflammatory activities of *Olax viridis* root bark extracts and fractions. *Int J Applied Res Nat Prod 2009; 2(1) 27-32.*
 10. Endocrinology 2012; 16(7): 91-96. Iwu M. Handbook of African medicinal plants. Boca Raton, FL: CRC Press; 1993.
 11. Dahanuka SA, Kulkarni RA, Rege NN. Pharmacology of medicinal plants and natural products. *Indian J Pharmacol 2002; 32: 508-512.*
 12. Iwu MW, Duncan AR, Okunji CO. New antimalarials of plant origin. In: Janick J, editor. *Perspective on new crops and new uses*. Alexandria: VA ASHS Press.1999; 457 – 462.
 13. Rodders J, Speedie M, Tyler V. *Pharmacognosy and harmacobiotechnology*. Baltimore: Williams and Wilkins.1996; 1-4.
 14. Mali RG, Mahale, NB. Evaluation of *Rhynchosia minima* (Linn.) DC leaves for anthelmintic activity, *International Journal of Pharmaceutical Sciences and Nanotechnology 2008; 1(2), 191-194.*
 15. Patwardhan B. *Ethnopharmacology and drug development*. J Ethnopharmacol 2005; 100:50-52.
 16. Yüksel N, Türkmen B, Kurdoğlu AH, Başaran B, Erkin J, Baykara T. Lubricant efficiency of magnesium stearate in direct compressible powder mixtures comprising cellactose® 80 and pyridoxine hydrochloride. *FABAD J Pharm Sci 2007; 32: 173-183.*
 17. Okoye EI, Onyekweli AO, Olobayo OK and Arhewoh MI (2010). Brittle fracture index (BFI) as a tool in the classification, grouping and ranking of some binders used in tablet formulation: Lactose tablets. *Sci Res Ess 5 (5): 500-506.*
 18. Harborne JB. *Phytochemistry*. Academic Press, London, pp. 89-131.
 19. Trease GE and Evans WC. *Pharmacology*. 15th Edn Saunders Publishers, London 2002, pp 42-44, 221-306, 331-393.
 20. *British Pharmacopoeia*. The Commission Office London. 2009; Vol. 111: 6578- 6585.
 21. Ikewuchi CC and Ikewuchi JC. Chemical profile of *Pleurotus tuberregium* (Fr) Sing's *Sclerotia*. *The Pacific J Sci Tech 2008; 10(1):28-30.*
 22. Edeoga HO, Okwu DE, Mbaebie BO. *Phytochemical Constituents of some Nigerian medicinal plants*. *Afri J Biotechnol 2005; 4 (7):685-688.*
 23. Ofoefule SI. *A text book of pharmaceutical technology and industrial pharmacy*. Samakin (Nig.) Enterprises, 2002; 26 – 65.